Pierre Fabre Pharmaceuticals, Inc
FDA inspection history in Parsippany, New Jersey, 2024
- 1
- Form 483
Every document, by year
- Form 483
2024: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2024One Form 483, at Parsippany, New Jersey.
Cited most
Across all Pierre Fabre Pharmaceuticals observations on file
- 21 CFR 314.80(c)(1)(i)Postmarketing reporting of adverse drug experiences2
The complete Pierre Fabre Pharmaceuticals file.
All 1 documents as original PDFs. For supplier audits, diligence and inspection prep.
Sites
Parsippany, New Jersey
One Form 483 · 2024 · 2 observations
Latest: Form 483, Nov 1, 2024 →
Documents
1 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2024-11-01 | 483 Form 483 | Parsippany, New Jersey | 2 | $99 |
Investigators on these documents
FEI number 3013144400 · most recent document Nov 1, 2024
About Pierre Fabre Pharmaceuticals, Inc
How many FDA Form 483s has Pierre Fabre Pharmaceuticals, Inc received?
FDA Intel has 1 Form 483 on file for Pierre Fabre Pharmaceuticals, Inc; the most recent is dated Nov 1, 2024.
When was Pierre Fabre Pharmaceuticals, Inc last inspected by FDA?
The most recent FDA inspection document on file for Pierre Fabre Pharmaceuticals, Inc is a Form 483 dated Nov 1, 2024, for the site in Parsippany, New Jersey.
What did FDA cite at Pierre Fabre Pharmaceuticals, Inc?
The regulations cited most in the observations on file for Pierre Fabre Pharmaceuticals, Inc are 21 CFR 314.80(c)(1)(i) (Postmarketing reporting of adverse drug experiences), 2 times.